Who will fund the next generation of diagnostic tests?


More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges.

Key question:

“…how does one generate a return from early stage diagnostic investing – the translation of academia-derived insights into new clinically-validated diagnostic tests. Who is going to fund the next generation of new innovative Dx plays?”

Unhealthy Prognosis for Venture-Backed Diagnostics – Forbes.


Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access